Andercore | $40,000,000 | (Feb 11, 2026)
Garner Health | $118,000,000 | (Feb 11, 2026)
NATILUS | $28,000,000 | (Feb 11, 2026)
Certified by Founder
Lodge
Dispatch Bio
start up
- 24/07/2025
- Series A
- Undisclosed Amount
Established in 2022, Dispatch Bio was founded with a bold purpose: to help create a world where all cancer patients can be cured. To achieve this, the company is engineering a universal treatment across solid tumors, leveraging its first-in-class Flare platform. This novel approach combines the strengths of immunotherapy with a tumor-specific viral vector, both engineered to clear tumor cells with precision and power. Dispatch has operations in Philadelphia and San Francisco, with access to world-class researchers.
- Industry Biotechnology Research
- Website https://dispatchbio.com/
- LinkedIn https://www.linkedin.com/company/dispatch-bio/
tem | $75,000,000 | (Feb 11, 2026)
Entire | $60,000,000 | (Feb 11, 2026)
Lema AI | $24,000,000 | (Feb 11, 2026)
ZeroDrift | $2,000,000 | (Feb 11, 2026)
Force Equals | $2,200,000 | (Feb 11, 2026)
Bretton AI | $75,000,000 | (Feb 11, 2026)
Pelgo | $5,500,000 | (Feb 11, 2026)
Newo.ai | $25,000,000 | (Feb 11, 2026)
Equal Parts | $23,000,000 | (Feb 11, 2026)